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In adolescent bone sarcoma patients, bone mass acquisition is potentially compromised 
at a time in which it should be at a maximum. To evaluate the problem we measured 
bone mineral density (BMD) and serum markers of bone formation and resorption in a 
series of pediatric patients with bone tumors. BMD was measured by dual-energy x-ray 
absorptiometry, at clinical remission, for lumbar spine and the neck of the femur in 38 
osteosarcoma and 25 Ewing’s sarcoma patients. Mean age was 20.65 and 19.13 y 
respectively. Serum markers of bone metabolism were: OC, PICP, ICTP, 25-OH vit D 
and 1,25-(OH)2 vit D, IGF-I, IGFBP-3 and intact PTH. Serum was sampled throughout 
anti-tumoral treatments and follow-up. We analyzed 85 samples from 59 osteosarcoma 
patients and 54 samples from 36 Ewing’s sarcoma patients. Patients had decreased 
lumbar and femoral BMD. The decrease was more pronounced in pubertal patients 
compared with those who had completed pubertal development at the time of disease 
diagnosis. Multivariate analysis indicated that sex, age, weight and BMI were 
significant in lumbar BMD depletion. Weight and BMI were significant in femoral 
BMD depletion. Serum markers of bone formation (PICP and OC) and resorption 
(ICTP) were, throughout, lower than reference values. Significant alterations in other 
markers were also observed. Up to a third of osteosarcoma and Ewing’s sarcoma 
patients in clinical remission had some degree of BMD deficit. The corresponding 






25-OH vit D, 25-hydroxyvitamin D; 1,25-(OH)2 vit D, 1,25-di hydroxyvitamin D; ALL, 
acute lymphoblastic leukaemia; BMD, bone mineral density; BMI, body mass index; 
DXA, dual energy X-ray absorptiometry; ICTP, cross-linked telopeptide of type 1 
collagen; OC, osteocalcin; PICP, procollagen type I C-terminal peptide; PTH, 
parathormone; SDS, standard deviation score. 
INTRODUCTION 
 
Bone growth and mineralization begin during fetal development and continue, at 
different rates, throughout infancy and adolescence until the accrued bone mass peak in 
the third decade of life (1). During infancy and adolescence two processes are involved 
in bone mass acquisition: bone neoformation from the growth cartilage (endochondral 
ossification) and remodeling of previously synthesized bone (2). If an optimal peak 
bone mass is not attained during adolescence, the risk of osteoporosis and pathologic 
fractures during adulthood is increased. 
 
There are various studies of bone growth and maintenance in child cancer patients but 
few large series are available (3–5). Best studied have been children treated for acute 
lymphoblastic leukemia (ALL) who are particularly at risk for bone mineral density 
(BMD) deficits after cranial irradiation (6–8). Some pediatric solid tumors have been 
included in the larger series, which tend to be rather heterogeneous, but there is scant 
BMD data for pediatric bone sarcomas, osteosarcomas and Ewing’s sarcomas (9). 
 
Children undergoing anti-tumoral treatments are at risk from several factors that may 
interfere in bone mass acquisition and maintenance. These factors include: the 
suboptimal nutritional status, prolonged immobilization, hormonal disorders, 
hypogonadism and treatments with chemotherapy, radiotherapy and with 
glucocorticoids. These factors have a strong impact on patients with bone tumors 
because such tumours are typically diagnosed during puberty when bone mass 
acquisition is at a maximum (10). 
 
Although alteration of bone metabolism and mineralization is a well-known secondary 
effect of chemotherapy, it is difficult to determine the specific effects of each 
chemotherapeutic agent on bone tissue due to the use of multiple drugs in the current 
anti-tumoral protocols for bone sarcomas. High-dose methotrexate (HD-MTX) is 
characteristic of osteosarcoma treatment and it has been suggested that methorexate 
(and also cyclophosphamide) have a particularly strong effect on bone mineral accretion 
and skeletal development (11). 
 
The aim of this longitudinal and retrospective study was to determine the scale of the 
alteration in bone mineral metabolism, at clinical remission and throughout the anti-
tumoral treatment, for a homogeneous group of survivors of malignant bone tumors 
(osteosarcoma and Ewing’s sarcoma). 
 
 
PATIENTS AND METHODS 
 
All the patients included in this study were treated and followed up at the Oncology 
Unit of the Department of Pediatrics of the University Clinic in Pamplona, Spain. 
Ethical approval was granted by the Ethics Committee of the University Clinic and in 
all cases informed consent was obtained from the patient or from parents. 
 
Patients who had other diseases (additional to the bone tumor) which might affect bone 
metabolism, and patients for whom there was incomplete information about the 
treatment protocol (type and dose of cytostatic drugs), evolution and/or complications 
were excluded from this study. 
The location of primary tumors, according to whether or not they affected weight-
bearing bones, is given in Table 1. Information, extracted from medical records, about 




BMD quantification by dual energy X-ray absorptiometry 
 
BMD was measured at clinical remission for 38 patients with osteosarcoma (20 female, 
18 male) and for 25 with Ewing’s sarcoma (11 female, 14 male). Mean age at BMD 
measurement was 20.65 y (SD, 4.42) for osteosarcoma patients and 19.13 (SD, 4.20) for 
Ewing’s sarcoma patients. Mean duration of remission was 6.12 y (SD, 3.67) (over 5 y 
in 52.6% of cases) in patients with osteosarcomas, and 6.11 y (SD, 3.73) (over 5 y in 
57.7% of cases) in patients with Ewing’s sarcomas. 
 
Areal bone mineral densities (areal-BMD, g/cm2) at the lumbar spine (L2-L4) and the 
neck of the right femur (left femur if the primary location was the right femur) were 
measured by dual energy x-ray absorptiometry (DXA; Hologic QDR 4500W v9.8 Elite, 
Woltham, MA). The short-term reproducibility expressed as the coefficient of variation 
for both determinations was 0.8% to 1%. To make our data (expressed in g/cm2) 
comparable to those of the Spanish reference population, which have been determined 
by Lunar-DXA (12,13), we applied the formula described by Genant et al. (14). Thus 
transformed, our data were compared with that of the reference population and the 





Standing height was measured with a Harpender stadiometer (Holtain Ltd., Crymych, 
UK) and always by a trained operator. Body weight was measured with a digital scale 
(Seca, Hanover, MD) with a sensitivity of 100g. Patients were weighed barefoot and 
after overnight fasting. The anthropometric data were obtained at the time of BMD 
determination. Height, weight and body mass index (BMI, kg/m2) were compared with 
those of the Spanish reference population (15) and expressed as SD scores (SDS). 
 
 
Analytical methods: Biochemical and hormonal markers of bone metabolism 
 
We analyzed 85 serum samples from 59 osteosarcoma patients and 54 serum samples 
from 36 Ewing’s sarcoma patients. Patients with altered hepatic and/or renal function 
and endocrinologic disorders were excluded. Thus, we excluded 12 osteosarcoma and 
four Ewing’s sarcoma patients due to hepatic disease (11 osteosarcomas and three 
Ewing’s sarcomas due to a transitory increase of transaminases, one osteosarcoma with 
chronic hepatic insufficiency and one Ewing’s sarcoma with cholelithiasis). We 
excluded 15 osteosarcomas and three Ewing’s sarcomas due to renal diseases (one 
osteosarcoma and two Ewing’s sarcomas due to hemorrhagic cystitis, three 
osteosarcomas and one Ewing’s sarcoma due to acute renal insufficiency, one 
osteosarcoma due to nephrolithiasis and five osteosarcomas due to tubulointerstitial 
nephropathy with chronic renal insufficiency). The above patients were excluded 
because, given the elimination pathways of the biochemical markers of bone formation 
and resorption, these renal and hepatic diseases could reasonably be expected to 
increase the serum levels of the markers. 
 
Samples were classified according to whether they had been extracted at diagnosis, at 
end of treatment, at remission or during tumoral progression (defined as the occurrence 
of disease at a distance from the primary tumor which required an additional anti-
tumoral treatment to the standard protocol) (Table 2). In all cases, plasma was obtained 
at 08:00 h whenever possible and stored at –80°C until use. 
 
To evaluate bone formation, intact osteocalcin (OC) (BioSource Europe, Nivelles, 
Belgium), procollagen type I C-terminal peptide (PICP) (Orion Diagnostica, Espoo, 
Finland) were measured by immunoradiometric assay (IRMA) and RIA (RIA) 
respectively. The sensitivity of the OC assay was 0.15 ng/mL and of the PICP assay was 
1.2 µg/L; the intra- and interassay coefficients of variation (CV) were 2.9–4.7% and 
5.3–6.3% for OC, and 3.1–3.2% and 4.0–5.8% for PICP, respectively. To evaluate bone 
resorption, cross-linked telopeptide of type 1 collagen (ICTP) (Orion Diagnostica, 
Espoo, Finland) was measured by RIA; the assay sensitivity was 0.5 µg/L; the intra- and 
interassay CV was 2.8–6.2% and 4.1–7.9%, respectively. To evaluate the growth 
hormone axis, serum IGF I (IGF-I) and IGF binding protein 3 (IGFBP-3) (Diagnostic 
Systems Laboratories Inc., Webster, TX, U.S.A.) were analyzed by IRMA; the assay 
sensitivity was 0.8 and 0.5 ng/mL; the intra- and interassay CV were 3.0% and 4.3% for 
IGF-I and 3.0% and 2.1% for IGFBP-3, respectively. To evaluate vitamin D 
metabolism, serum concentrations of 25-hydroxyvitamin D (25-OH vit D) and 1,25-di 
hydroxyvitamin D (1,25-(OH)2 vit D) (BioSource Europe, Nivelles, Belgium) were 
measured by RIA; the assay sensitivity was 0.6 ng/mL and 1.0 pg/mL; the intra- and 
interassay CV were 6.1–7.9% and 7.1–8.2% for 25-OH vit D and 7.8–12.4% and 10-
12.1% for 1,25-(OH)2 vit D, respectively. Intact parathormone was measured by 
chemiluminescent enzyme immunometric assay (PTH, Diagnostic Products 
Corporation, Los Angeles, CA); the assay sensitivity was 1 pg/mL; the intra- and 
interassay CV was 5.4–7.0% and 5.0–5.5%, respectively. Standard methods were used 
for thyroid-stimulating hormone (TSH) evaluation (Abbott Laboratories, Illinois) to 
exclude hyper and hypothyroidism; follicle stimulating hormone (FSH), LH (LH) 
(Abbott Laboratories, Illinois), testosterone in males and estradiol in females to exclude 





Statistical analyses were carried out with SPSS v11.0 (Statistical Package for the Social 
Sciences, Chicago) and values of p < 0.05 were considered significant. We used the 
Student t-test to compare the SDS or Z-scores obtained from patient data and Spanish 
reference population data. 
 
The variation of anthropometric values and BMD according to age, sex, type of tumor 
and remission duration was evaluated with the Student t-test for independent samples or 
by the Mann-Whitney U-test.  
 
The correlation between BMD of patients in clinical remission and the clinical factors 
potentially involved in BMD was evaluated by multiple linear regression (Table 3). 
 
The relationship between serum markers of bone resorption/formation and BMD (DXA 
values) was determined by Spearman’s correlation. 
  
The relationship between PICP and ICTP and the remission time until determination 
was established by the median test and the Mann-Whitney U-test for the five-year cut-
off. The scoring of biochemical and hormonal markers according to the reference ranges 






Bone mineral density determination by DXA. The lumbar and femoral BMD of our 
pediatric bone cancer patients was significantly lower than that of the sex and age-
paired reference population (Table 4). Male osteosarcoma patients had lower BMD than 
female patients (p = 0.04). We found no significant difference in BMD, whether lumbar 
or femoral, of patients with osteosarcoma compared with that of patients with Ewing’s 
sarcoma. Neither did we find any association between BMD and the time lag from the 
end of treatment until the moment of BMD measurement. 
 
On the basis of lumbar and femoral BMD respectively, 33.9% and 25.4% of patients 
had BMD in the range between –1 and –2 SDS. Similarly, 9.7% and 17.5% of patients 
had BMD of less than –2 SDS (Fig. 1). The incidence of fractures was also studied but 
no significant differences were detected between groups. In addition to the 17 patients 
with pathologic fractures, as a consequence of the tumor and/or the anti-tumoral 
treatments 18 patients presented infections of the peri-tumoral soft tissues, seven 
chronic osteomyelitis, and a further three had to have a limb amputated. 
 
BMD was related to age at diagnosis and treatment onset. Lumbar BMD in pubertal 
patients was significantly lower than that of the reference population (p < 0.001) and, 
furthermore, tended to be lower than that of patients who had completed pubertal 
development at the time of diagnosis (p = 0.08). The difference from the reference 
population was even more pronounced for femoral BMD in osteosarcomas and Ewing’s 
sarcomas (p < 0.001 and p = 0.003 respectively). 
 
We used multiple linear regression to analyze the relation-ship between BMD of 
patients in clinical remission and the clinical factors potentially involved in BMD. 
 
Multivariate analysis indicated that the following factors had statistically significant 
effects on lumbar BMD: sex (p = 0.002 and p = 0.012 for areal-BMD and BMD-SDS 
respectively, BMD being higher in women than in men), age at diagnosis (p = 0.035 for 
areal-BMD with BMD increasing with older age) and age DXA (p < 0.001 for BMD-
SDS with BMD increasing with older age). Concerning the anthropometric data, only 
weight (p = 0.016 for areal-BMD) and BMI (p = 0.038 for BMD-SDS) had a significant 
positive effect on BMD. Months in clinical remission showed positive correlation in the 
univariate analysis of areal-BMD (p = 0.017). Height did not influence BMD in our 
series, although height was statistically higher than that of the reference population. 
           
With regard to femoral BMD, the following factors had significant effects on BMD: 
both weight (p = 0.001, for areal-BMD) and BMI (p = 0.001, for BMD-SDS) showed a 
positive effect on BMD, and vincristine dose showed a weak negative effect on areal-
BMD (p = 0.037). Surprisingly, the HD-MTX received by the osteosarcoma patients did 
not statistically affect the lumbar BMD. The total duration of hospitalization showed a 
weak negative correlation with femoral areal-BMD (p = 0.065). 
 
 
Analysis of the biochemical and hormonal markers of bone metabolism  
 
At diagnosis, at the end of the anti-tumoral treatment, at clinical remission and at tumor 
progression, the serum levels of biochemical markers of bone formation (PICP y OC) 
and resorption (ICTP) were significantly lower than reference values (p < 0.001) (Table 
5). Three patients (18.7%) had increased levels of ICTP at the end of treatment and six 
(26.1%) had increased levels at tumor progression. 
 
The number of patients with normal ICTP levels increased linearly with time after 
completion of the anti-tumoral treatment (p < 0.001) up to a maximum at five years in 
clinical remission. 
 
In comparison to reference values, patient levels of IGF-I and PTH were lower both at 
the time of diagnosis (p = 0.005 and p = 0.02 respectively) as well as at clinical 
remission (p < 0.001). Similarly, patients at remission had lower levels of 1,25-(OH)2D 
(p < 0.001). Concerning patients in disease progression, a significant number had low 
levels of PTH (33.3%), 1,25-(OH)2D (15.8%) and 25-OH vit D (26.3%); while three 
(14.3%) and six (50%) of those patients showed increased ICTP and IGF-I respectively. 
  
With regard to gonadotrophins and sex hormones, four patients (4.4%) had increased 
FSH and LH levels, two of them immediately after pelvic radiotherapy and two at 
disease progression. Two other patients had low levels of gonadotrophins after cranial 
radiotherapy. 
 
The markers of bone formation (PICP and OC) and resorption (ICTP) were negatively 






Malignant bone tumors are the third most common tumor type among adolescents and 
young adults, with a peak incidence at about 15 y of age. Frequently, the diagnosis of 
these tumors occurs during the period of maximal growth rate and bone accrual, the 
pubertal growth spurt. A question that we wished to address was: what are the 
secondary effects of undergoing a tumoral process and its treatment during this specific 
period of life? 
 
The first studies of bone mass in pediatric oncology involved children with ALL (6–
8,16–18). Most researchers concluded that there was a depletion of bone mass which 
could be detected at the time of diagnosis and that persisted in adult survivors. In some 
studies, patients with ALL were compared with a heterogeneous mix of patients with 
“other malignant tumors” which included lymphomas, CNS (CNS) tumors and 
sarcomas (3,4,19–21). The usefulness of such comparisons is somewhat limited by the 
very different clinical and etiopathogenic natures of the tumors concerned. 
 
While the low bone mass of all patients can be attributed to their low stature, both 
osteosarcoma and Ewing’s sarcoma survivors are significantly taller than the reference 
population (22). This raises the question of whether the reduced BMD of a bone tumor 
survivor is a consequence of the anti-tumoral treatment or of the tumor itself. 
 
Several authors have observed that weight is associated with BMD and bone mineral 
content both in healthy children (23–25) and cancer survivors (3,26). However, 
Mølgaard and collaborators (27) demonstrated that bone surface area corrected by 
height (to give an estimate of bone width) increased with weight and that therefore the 
effect of weight on bone mineral content was indirect. 
 
Typically, bone tumors are diagnosed at an older age than leukemias and other tumor 
types. For this reason the average age of our patients at clinical remission and, therefore, 
at BMD determination was approximately 20 y. Bone tumors typically occur during 
pubertal development. The influence of the pubertal period on bone mass has been 
demonstrated by many authors (12,23,28,29). Some publications indicate that, 
independent of the age at tumor diagnosis, low BMD at an age when it should be 
maximal is a high risk factor for osteoporosis (4).  
  
Contrary to other publications (19–21,30), in our series, age at diagnosis and at DXA 
were determining factors for lumbar BMD, which was more severely affected in those 
patients who were pubertal at the time of diagnosis than in those who had already 
completed pubertal development. 
 
Holzer et al. analyzed the BMD of long term (>10 y) osteosarcoma survivors and 
detected that 43.7% had BMD values in the range of osteopenia and 20.8% in the range 
of osteoporosis (9). Similarly, the patients reported here showed significantly decreased 
BMD values, with an even higher incidence of osteopenia (59.7%) and osteoporosis 
(27%). However, whilst Holzer et al. used T-scores (comparison with the maximum 
young adult BMD) we transformed our data in Z-scores (comparison against age and 
gender-matched controls). Furthermore, the mean age at diagnosis was lower in the 
patients reported here. Despite the above differences, it can be concluded from both 
studies that a high number of bone sarcoma survivors show some degree of BMD 
deficit at an age at which BMD should be at its peak. Considering that a deficit of BMD 
of one SD increases the risk of pathologic fractures 2.5-fold, such a deficit has 
important repercussions on future quality of life. 
 
As mentioned above, an effect of anti-tumoral treatment on pubertal development and 
on bone mass acquisition has been frequently reported. The pubertal development of our 
patients at the time of diagnosis was concordant with their age and, although many of 
the young women developed amenorrhea during treatment, we did not detect any 
hormonal alterations at remission. There were no significant differences between the 
men and women in terms of BMD or biochemical markers. 
 
Osteopathy due to methotrexate is a well known secondary effect (31); however, in our 
study, neither methotrexate, cyclophosfamide nor cisplatin affected BMD. We detected 
a slight effect of vincristine on femoral BMD only. Our results should be interpreted 
with a degree of caution due to the limited number of patients involved although the 
results do corroborate similar reports by other authors (3,6,19–21) of a lack of effect of 
chemotherapy agents on BMD. 
 
Another important factor with an influence on BMD in survivors of malignant tumors is 
the degree of immobilization and physical inactivity during treatment. Apart from 
orthopedic considerations, bone tumors are most often located in the lower limbs and 
this tends to complicate physical exercise. As an estimate of immobilization we used the 
total duration of hospitalization and observed that this tended to be negatively 
associated with BMD. This same finding has been detected for different tumors by other 
authors (20) who suggested that, being one of the main bones supporting body weight, 
the femur might be specifically affected by immobilization. The important effect on of 
bone in young persons shortly after chemotherapy would support a hypothesis that 
femur osteoporosis is induced by immobilization and that the more metabolically active 
lumbar spine is affected by chemotherapy, corticoids and/or hormonal disorders. 
 
In patients who showed an asymmetric load due to an effect of the tumor and/or 
treatment on weight-bearing structures, one might not be surprised to find a 
compensatory bone deposit on the non-affected, load-bearing femur due to over 
stimulation. Nevertheless, the measurement of BMD in the normal femoral neck 
showed a statistically significant decrease compared with the reference population of 
paired sex and age. 
 
With regard to the question of whether the adverse effects of anti-tumoral treatment on 
bone metabolism and mineralization are reversible or not, the published data (3,6,31,32) 
is controversial and inconsistent. In our series, we detected a weak positive correlation 
between remission time and lumbar BMD but the catch-up is not complete and 
contributes to the high risk of developing osteoporosis in the future decades of life. 
 
Longitudinal analysis of hormonal and biochemical markers of bone metabolism has 
several advantages over quantification of bone mass; it gives information on the global 
metabolic status, can detect subtle alterations over short periods of time, is independent 
of the observer and gives information on the mechanisms involved in any associated 
clinical alteration. 
 
In our series, the levels of markers of bone metabolism were typically below normal at 
diagnosis and then gradually normalized over the duration of the treatment and patient 
evolution. This process was particularly noticeable for ICTP, a marker of bone 
resorption. Nevertheless, values remained below normal ranges, which could account 
for the low BMD detected by DXA at remission. Growth hormone deficiency and 
persistent alterations in levels of vitamin D and calcium were also detected in some 
patients, which could be an indirect indicator of a sub-optimal normalization of bone 
metabolism and could suggest a higher osteoporosis risk in adulthood. 
 
Compared with ALL patients, osteosarcoma and Ewing’s sarcoma patients are 
diagnosed and treated at an older age which coincides with the period of maximal bone 
mass accrual. The timing of the tumor and treatment at such a critical period of life 
implies an interference that can influence the future quality of life of patients. 
 
Some of the main limitations in the interpretation and comparison of the results of bone 
mass studies in survivors of pediatric bone sarcomas are the small number of patients, 
the heterogeneity of treatments, the occurrence of clinical complications, the different 
databases for calculation of BMD Z-scores and the different methods for determining 
BMD (areal versus volumetric BMD). 
 
Despite the above limitations, we can report a reduction in BMD in osteosarcoma and 
Ewing’s sarcoma patients in clinical remission and conclude that these patients suffer 
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Table 1. Classification of primary tumors according to their location in 
weight-bearing bones 
Type of bone Osteosarcoma (%) Ewing’s sarcoma (%) 
Weight-bearing bones   
Tibia 46 28 
Femur 37 16 
Pelvis 0 8 
Non-weight-bearing bones* 17 48 







Table 2. Distribution, by sampling schedule, of the samples obtained for 
analysis of biochemical and hormonal markers of bone metabolism 
 Osteosarcoma Ewing’s sarcoma Total 
At diagnosis 8 6 14 
End of treatment 10 6 16 
Clinical remission 54 32 86 

























Table 3. Description of the clinical factors included in the analysis of the 
BMD in pediatric patients with bone tumors at clinical remission 
 Osteosarcoma Ewing´s sarcoma 
Age at diagnosis (years) 13.79 (11.58; 15.08)* 12.06 (3.78)† 
Age at DXA(years) 20.65 (4.42) 19.13 (4.20) 
Height (cm) 169.49 (10.01) 169 (161.20; 176.0) 
Height (SDS) 0.54 (1.33)‡ 0.14 (1.12) 
Weight (Kg) 60.83 (11.10) 61.37 (15.94) 
Weight (SDS) 0.30 (-0.55; 0.85) -0.20 (-0.50; 0.85) 
BMI (Kg/m2) 20.67 (19.25; 22.88) 21.16 (18.24; 22.98) 
BMI (SDS) 0 (-0.75; 0.55) 0.10 (-0.80; 0.75) 
Treatment duration (months) 12 (11; 15) 11 (10.5; 15.5) 
Hospitalization (months) 6.46 (4.96; 9.11) 4.96 (3.36; 7.25) 
Remission time (years) 5.92 (3.14; 9.26) 5 (3.0; 8.21) 
Cytostatic drugs   
Methotrexate (g/m2) 62.77 (41.15; 90.10) 0.23 (0.21; 0.28) 
Cyclophosphamide (g/m2) 4.47 (2.20) 17.71 (14.66; 21.78) 
Bleomycin (mg/m2) 100.10 (45.60) 173.95 (56.94) 
Cisplatin (mg/m2) 477.60 (131.70) — 
Adriamycin (mg/m2) 424.21 (114.37) 432.08 (134.03) 
Actinomycin D (mg/m2) 4.96 (2.06) 9.20 (2.91) 
Vincristine (mg/m2) 6.43 (3.12; 8.49) 21.49 (17.79; 32.18) 
* Median (interquartilic range). 
† Mean (standard deviation). 
‡ Height-SDS for osteosarcomas is significantly higher than that of the 















Table 4. Comparative analysis of the lumbar and femoral BMD in bone sarcoma patients compared                        
to the Spanish reference population (12, 15) 






















Osteosarcoma 38 0.96 (0.13) 1.08 (0.14) -0.76 (0.96) p < 0.001 0.85 (0.14) 0.85 (0.15) -0.88 (1.10) p < 0.001 
Females 20 0.99 (0.10) 1.11 (0.11) -0.46 (0.82) p = 0.020 0.84 (0.14) 0.84 (0.14) -0.85 (1.20) p = 0.005 
Males 18 0.92 (0.16) 1.05 (0.16) -1.11 (1.02) p < 0.001 0.86 (0.15) 0.87 (0.15) -0.91 (1.01) p = 0.001 
Ewing´s 
sarcoma 25 0.93 (0.16) 1.06 (0.17) - 0.84 (1.05) p = 0.001 0.88 (0.15) 0.88 (0.15) -0.76 (1.15) p = 0.003 
Females 11 0.97 (0.12) 1.09 (0.14) -0.74 (1.20) p = 0.068 0.83 (0.14) 0.84 (0.14) -0.90 (1.14) p = 0.025 
Males 14 0.90 (0.19) 1.03 (0.20) -0.92 (0.95) p = 0.003 0.92 (0.16) 0.92 (0.15) -0.64 (1.18) p = 0.063 
* BMD measured by the Hologic system and expressed as mean (standard deviation). 
† BMD measured by the Lunar system and expressed as mean (standard deviation). 
‡ BMD measured by the Lunar system, compared to the Spanish reference population and expressed as Z-score. 






Table 5. Absolute values of the biochemical and hormonal markers of bone metabolism                                   
in pediatric patients with bone tumors 
Marker Diagnosis End of treatment Clinical remission Tumor progression 
PICP (µg/L) 49.30 (30.16; 73.95) 74.05 (50.10; 104.53) 49.29 (39.02; 63.42) 58.77 (42.57; 94.19) 
ICTP (µg/L) 5.15 (3.04; 6.92) 6.43 (4.68; 11.62) 2.90 (1.96; 4.58) 6.09 (4.48; 10.53) 
OC (ng/mL) 3.89 (2.61; 5.99) 3.51 (2.07; 6.96) 4.17 (2.56; 8.18) 3.81 (1.98; 7.75) 
PTH (pg/mL) 17.40 (10.47; 20.22) — 11.90 (9.00; 16.30) 12.40 (10.70; 20.70) 
IGF-I (ng/mL) 109.5 (67.5; 159) — 98.10 (68.97; 150.25) 89.40 (51.65; 139.5) 
IGFIBP3 (ng/mL) 1335.5 (1077; 1688) — 1331.5 (1068; 1621) 1293 (875; 1405) 
1,25-(OH)2 vit D (pg/mL) — — 26.05 (21.00; 31.07) 32.14 (19.03; 44.27) 
25-OH vit D (ng/mL) — — 19.83 (14.07; 23.31) 13.29 (9.21; 17.94) 





Figure 1. Representation of bone mineral density (BMD) in pediatric bone sarcoma 
patients at clinical remission. □ osteosarcoma; ■ Ewing’s sarcoma. Lumbar spine: 21 
patients had a BMD in the range between –1 and –2 SDS and 6 of less than –2 SDS; 
femoral neck: 16 patients had a BMD in the range between –1 and –2 SDS and 11 of 
less than –2 SDS 
 
 
